<DOC>
	<DOCNO>NCT00419692</DOCNO>
	<brief_summary>This study RLS patient design assess affect food absorption , distribution , metabolism excretion ropinirole ( dose patient fasted state patient follow high-fat breakfast ) , assess difference absorption , distribution , metabolism excretion ropinirole patient give two 3mg ropinirole tablet versus one 6mg tablet .</brief_summary>
	<brief_title>Restless Legs Patient Study On Absorption , Distribution , Metabolism And Excretion Of Ropinirole And The Effect Of Food</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criterion : Patients diagnosis RLS Body mass index 18 32 kg/mÂ² , body weight least 50 kg Normal blood pressure prestudy Light smoker ( &lt; 20/day ) Exclusion criterion : History postural hypotension faint Secondary RLS Patients suffer primary sleep disorder RLS Patients diagnose movement disorder Patients unstable medical condition Patients personal family history adverse reaction hypersensitivity study drug Patients abnormal laboratory value Patients hepatitis HIV Patients abuse alcohol drug Patients take follow medication : dopamine agonist ( include ropinirole ) , dopamine antagonist ( e.g. , metoclopramide domperidone ) , levodopa/carbidopa</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>formulation ,</keyword>
	<keyword>control release RLS ,</keyword>
	<keyword>pharmacokinetic ,</keyword>
	<keyword>RLS</keyword>
	<keyword>food effect ,</keyword>
	<keyword>SK &amp; F101468 ,</keyword>
</DOC>